Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jul 23, 2026
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells $226,027.34 in Stock
05:40am, Sunday, 18'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) CEO Cedric Francois sold 10,186 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an a
Is Apellis Pharmaceuticals' FDA Win Just the Beginning?
05:36am, Saturday, 17'th Jan 2026
When Apellis Pharmaceuticals (APLS) secured FDA approval for EMPAVELI in C3 glomerulopathy and IC-MPGN last summer, the stock was trading near $28.
Apellis Stock Crashes 23% in a Week: Here's What You Should Know
12:21pm, Thursday, 15'th Jan 2026
APLS stock plunges 23% in a week after reporting $190 million in preliminary Q4 U.S. net product revenues, as weaker Syfovre sales and mixed Empaveli uptake disappoint investors.
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
06:16pm, Monday, 12'th Jan 2026
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 12'th Jan 2026
WALTHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced preliminary U.S. net product revenues for the fourth quarter and the full year 2025, as
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 05'th Jan 2026
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44th Annual J.P.
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
05:05pm, Wednesday, 03'rd Dec 2025
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phas
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript
04:43pm, Wednesday, 03'rd Dec 2025
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
06:53pm, Tuesday, 02'nd Dec 2025
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 25'th Nov 2025
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conf
Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Apellis Pharmaceuticals, Inc. $APLS
04:34am, Monday, 17'th Nov 2025
Connor Clark and Lunn Investment Management Ltd. lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) by 10.0% in the undefined quarter, according to its most recent filing
Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript
04:41pm, Wednesday, 12'th Nov 2025
Apellis Pharmaceuticals, Inc. ( APLS ) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
07:00am, Wednesday, 12'th Nov 2025
WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continu
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
07:00am, Wednesday, 05'th Nov 2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, Nove
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
03:21pm, Friday, 31'st Oct 2025
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
